Literature DB >> 8414154

IgG subclasses of antineutrophil cytoplasm autoantibodies (ANCA).

M Segelmark1, J Wieslander.   

Abstract

Sera that had been positive in routine ELISA for ANCA were studied retrospectively for the IgG subclass distribution of these autoantibodies. An ELISA previously developed for measurement of IgG subclasses of anti-GBM antibodies was modified for this purpose. Of a total of 247 sera, 114 were found to be positive in at least one of the assays for IgG subclasses of anti proteinase 3, 72 of these patients were men and 42 were women, giving a ratio of 1.8. Also 134 sera were positive in at least one of the IgG subclass assays for antimyeloperoxidase (MPO), with a male/female ratio of 0.97. The ANCA seem to consist mainly of IgG1 and IgG4 autoantibodies. Among the anti-MPO group, IgG2 is relatively common and IgG3 is scarce. Contrasting with this, IgG3 is relatively common in the antiproteinase 3 group. In this group high IgG2 titres are rare. Twelve sera were found to be positive for both autoantigens. Clinical data were studied for 44 patients. Prognosis for old patients was found to be poor. Patients with inactive disease were often positive in only one subclass assay, while patients with active disease were positive in two or more subclass assays (P < 0.01).

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8414154     DOI: 10.1093/ndt/8.8.696

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  26 in total

1.  Antineutrophil cytoplasmic antibodies in Bulgarian patients with rheumatoid arthritis: characterization and clinical associations.

Authors:  Irena Manolova; Maria Dantcheva
Journal:  Rheumatol Int       Date:  2004-11-11       Impact factor: 2.631

2.  Immunoglobulin subclass determines ability of immunoglobulin (Ig)G to capture and activate neutrophils presented as normal human IgG or disease-associated anti-neutrophil cytoplasm antibody (ANCA)-IgG.

Authors:  T Pankhurst; G Nash; J Williams; R Colman; A Hussain; C Savage
Journal:  Clin Exp Immunol       Date:  2011-03-10       Impact factor: 4.330

3.  A comparison of the characteristics of circulating anti-myeloperoxidase autoantibodies in vasculitis with those in non-vasculitic conditions.

Authors:  I C Locke; B Leaker; G Cambridge
Journal:  Clin Exp Immunol       Date:  1999-02       Impact factor: 4.330

4.  Alternative complement pathway activation products in urine and kidneys of patients with ANCA-associated GN.

Authors:  Shen-Ju Gou; Jun Yuan; Chen Wang; Ming-Hui Zhao; Min Chen
Journal:  Clin J Am Soc Nephrol       Date:  2013-10-10       Impact factor: 8.237

5.  The expression of Toll-like receptors 2, 4 and 9 in kidneys of patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis.

Authors:  H Wang; S-J Gou; M-H Zhao; M Chen
Journal:  Clin Exp Immunol       Date:  2014-09       Impact factor: 4.330

6.  Complement regulatory proteins in kidneys of patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis.

Authors:  L Cheng; S-J Gou; H-Y Qiu; L Ma; P Fu
Journal:  Clin Exp Immunol       Date:  2017-10-20       Impact factor: 4.330

Review 7.  Anti-neutrophil cytoplasmic autoantibodies (ANCA) and vasculitis.

Authors:  B Baslund; A Wiik
Journal:  Clin Rev Allergy       Date:  1994

8.  No association between neutrophil FcgammaRIIa allelic polymorphism and anti-neutrophil cytoplasmic antibody (ANCA)-positive systemic vasculitis.

Authors:  W Y Tse; S Abadeh; A McTiernan; R Jefferis; C O Savage; D Adu
Journal:  Clin Exp Immunol       Date:  1999-07       Impact factor: 4.330

9.  Hypogalactosylation of serum IgG in patients with ANCA-associated systemic vasculitis.

Authors:  M Holland; K Takada; T Okumoto; N Takahashi; K Kato; D Adu; A Ben-Smith; L Harper; C O S Savage; R Jefferis
Journal:  Clin Exp Immunol       Date:  2002-07       Impact factor: 4.330

10.  Some patients with anti-myeloperoxidase autoantibodies have a C-ANCA pattern.

Authors:  M Segelmark; B Baslund; J Wieslander
Journal:  Clin Exp Immunol       Date:  1994-06       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.